Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases

NCT01442935 is registered in ClinicalTrials.gov with UNICANCER as lead sponsor.

NCT NCT01442935
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01442935 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Multicentric Randomized Trial, Evaluating the Best Protocol of Chemotherapy, Associated With Targeted Therapy According to the Tumor KRAS Status, in Metastatic Colorectal Cancer (CCRM) Patients With Initially Non-resectable Hepatic Metastases
Lead sponsor
UNICANCER
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
January 31, 2021
Enrollment
256 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer